2Trelle S,Reichenbach S,Wandel S,et al.Cardiovascular safety of non-steroidal anti-inflammatory drugs:network meta-analysis NSAID and car-diovascular safety[J].BMJ,2011;342:c6618.
3McGettigan P,Henry D.Cardiovascular risk and inhibition of cyclooxyge-nase:a systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase2[J].JAMA,2006;296:1633-44.
4White B.Risk of cardiovascular events in patients receiving celecoxib:a meta-analysis of randomized clinical trials[J].Am J Cardiol,2007;99:91-8.
5Sakamoto C,Soen S.Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthri-tis in Japan[J].Digestion,2011;83(1-2):108-23.
6Solomon DH,Rassen JA,Glynn RJ,et al.The comparative safety of anal-gesics in older adults with arthritis[J].Arch Intern Med,2010;170(22):1968.
7Brophy JM,Lévesque LE,Zhang B.The coronary risk of cyclo-oxygenase-2inhibitors in patients with a previous myocardial infarction[J].Heart,2007;93(2):189-94.
8Andersohn F,Suissa S,Garbe E.Use of first-and second-generation cy-clooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction[J].Circulation,2006;113(16):1950-7.
9St Germaine CG,Bogaty P,Boyer L,et al.Genetic polymorphismsand the cardiovascular risk of non-steroidal anti-inflammatory drugs[J].Am J Cardiol,2010;105(12):1740-5.
10Anning PB,Coles B,Morton J,et al.Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors[J].Blood,2006;108(13):4059-62.
